Monotherapy of experimental metabolic syndrome: II. Study of cardiovascular effects

Vladimír Knezl 1 , Ružena Sotníková 1 , Zuzana Brnoliaková 1 , Tatiana Stankovičová 2 , Viktor Bauer 1  and Štefan Bezek 1
  • 1 Institute of Experimental Pharmacology and Toxicology, Slovak Academy of Sciences,, , 841 04, Bratislava, Slovakia
  • 2 Department of Pharmacology and Toxicology, Comenius University in Bratislava, Faculty of Pharmacy, 832 32, Bratislava 3, Slovakia


Metabolic syndrome belongs to the most important risk factors of cardiovascular diseases. The aim of this study was to investigate changes in cardiovascular system induced by high cholesterol and high fat diet (HCHF) in HTG rats and their influence by a pyridoindole antioxidant – SMe1EC2 (S). The effects of S were compared with those of atorvastatin (A). Male HTG rats were fed HCHF (1% cholesterol + 7.5% lard) for 4 weeks. S and A were administered p.o., 50 mg/kg b.w. Following experimental groups were used: Wistar rats (W), hypertriglyceridemic rats (HTG), HTG rats fed HCHF (CHOL), HTG+S (S-HTG), CHOL+S (S-CHOL), and CHOL+A (A-CHOL). Values of blood pressure (BP) and selected ECG parameters were monitored in conscious animals, functions of the isolated heart and aorta were analyzed ex vivo. At the end of the experiment, systolic (sBP) and diastolic (dBP) blood pressure was increased in HTG and CHOL. S and A decreased BP in all treated groups. Accordingly with BP changes, the aortic endothelial function of CHOL was damaged. Both S and A administration ameliorated the endothelium-dependent relaxation to values of W. PQ and QTc intervals were prolonged in CHOL, while the treatment with S or A improved ECG findings. Prodysrhythmogenic threshold was decreased significantly in CHOL and both treatments returned it to the control values. In conclusion, HCHF increased BP, impaired endothelial relaxation of the aorta and potentiated susceptibility of myocardium to dysrhythmias. The effect of S on the changes induced by HCHF diet was more pronounced than that of A.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Albarado-Ibañez A, Avelino-Cruz JE, Velasco M, Torres-Jácome J, Hiriart M. (2013). Metabolic syndrome remodels electrical activity of the sinoatrial node and produces arrhythmias in rats. PLoS One 8: e76534.

  • Alberti KG, Eckel RH, Grungy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr. (2009). Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 1640–1645.

  • Allesie MA, Lammers WJEP, Bonke IM, Hollen J. (1984). Intra-atrial reentry as a mechanism for atrial flutter induced by acetylcholine and rapid pacing in dog. Circulation 70: 123–135.

  • Bacharova L, Krivosikova Z, Wsolova L, Gajdos M. (2012). Alterations in the QRS complex in the offspring of patients with metabolic syndrome and diabetes mellitus: early evidence of cardiovascular pathology. J Electrocardiol 45: 244–251.

  • Benova T, Knezl V, Viczenczova C, Bacova BS, Radosinska J, Tribulova N. (2015). Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model. J Physiol Pharmacol 66: 83–89.

  • Bezek Š, Brnoliaková Z, Sotníková R, Knezl V, Paulovičová E, Navarová J, Bauer V. (2017). Monotherapy of experimental metabolic syndrome: I. Efficacy and safety. Interdiscip Toxicol 10(3): 100–105.

  • Broskova Z and Knezl V. (2011). Protective effect of novel pyridoindole derivatives on ischemia/reperfusion injury of the isolated rat heart. Pharmacol Rep 63: 967–974.

  • Dougherty PJ and Arora RR. (2012). Utility of early high dose statins in acute coronary syndrome. Am J Ther 19: 369–376.

  • Duflou J, Virmani R, Rabi I, et al. (1995). Sudden death as a result of heart disease in morbid obese. Am Heart J 130: 306–313.

  • Du Toit EF, Nabben M, Lochner A. (2005). A potential role of angiotensin II in obesity induced hypertrophy and ischaemic/reperfusion injury. Basic Res Cardiol 100: 346–354.

  • Galajda P, Mokáň M, Prídavková D, Tomásková V, Sutarík L, Krucinská L, Bukovská A, Rusnáková G. (2007). Prevalencia metabolického syndrómu na Slovensku. (Prevalence of metabolic syndrome in Slovakia. In Slovak). Int med 7: 325–331.

  • Gray RA, Pertsov AM, Jalife J. (1998). Spatial and temporal organization during cardiac fibrillation. Nature 392: 75–78.

  • Grundy SM. (2007). Controversy in Clinical Endocrinology. Metabolic Syndrome: A Multiplex Cardiovascular Risk Factor. J Clin Endocr Met 92: 399–404.

  • Horwich TB, MacLellan WR. (2007). Atorvastatin and statins in the treatment of heart failure. Expert Opin Pharmacother 17: 3061–3068.

  • Huang JV, Lu L, Ye S, Bergman BC, Sparagna GC, Sarraf M, Reusch JE, Greyson CR, Schwartz GG. (2013.) Impaired contractile recovery after low-flow myocardial ischemia in a porcine model of metabolic syndrome. Am J Physiol Heart C 304: H861–873.

  • Jain KS, Kulkarni RR, Jain DP. (2010). Current drug targets for antihyperlipidemic therapy. Mini Rev Med Chem 10: 232–262.

  • Jouven X, Charles MA, Desnos M, Ducimetière P. (2001). Circulating nonesterified fatty acid levels as a predictive risk factor for sudden death in the population. Circulation 104: 756–761.

  • Liptak B, Knezl V, Gasparova Z. (2017). Metabolic disturbances induce malignant heart arrhythmias in rats. Bratisl Med J 118: 539–543.

  • Liu C, Zhou M-S, Li Y, Wang A, Chadipiralla K, Tian R, Tian R, Raij L. (2017). Oral nicotine aggravates endothelial dysfunction and vascular inflammation in diet-induced obese rats: Role of macrophage TNFα. PLoS ONE 12: e0188439.

  • Kihara Y and Morgan JP. (1991). Intracellular calcium and ventricular fibrillation. Circ Res 68: 1378–1389.

  • Kurl S, Laaksonen DE, Jae SY, Mäkikallio TH, Zaccardi F, Kauhanen J, Ronkainen K, Laukkanen JA. (2015). Metabolic syndrome and the risk of sudden cardiac death in middle-aged men. Int J Cardiol 203: 792–797.

  • Lew EA and Garfinkel L. (1979). Variations in mortality by weight among 750 000 men and woman. J Chron Dis 32: 563–576.

  • Luscher TF, Creager MA, Beckman JA, Cosentino F. (2003). Diabetes and vascular disease: patophysiology, clinical consequences, and medical therapy: part II. Circulation 108: 1655–1661.

  • Luu M, Stevenson WG, Stevenson LW, Baron K, Walden J. (1989). Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 80: 1675–80.

  • Merrilat JC, Lakatta EG, Hano O, Guarnieri T. (1990): Role of calcium and the calcium channel in the initiation and maintenance of ventricular fibrillation. Circ Res 67: 115–1123.

  • Mikhin VP, Zhilyaeva YA, Gromnaky NI. (2016). Pleotropic effects of atorvastatin in patients with chronic ischemic heart disease. Kardiologiia 56: 42–46.

  • Nduhirabandi F, Du Toit EF, Blackhurst D, et al. (2011). Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of diet-induced obesity. J Pineal Res 50: 171–182.

  • Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S. (2016). Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol 72: 859–867.

  • Ooie T, Kajimoto M, Takahashi N, Shinohara T, Taniguchi Y, Kouno H, Wakisaka O, Yoshimatsu H, Saikawa T. (2005). Effects of insulin resistance on geranylgeranylacetone-induced expression of heart shock protein 72 and cardioprotection in high-fat diet rats. Life Sciences 77: 869–881.

  • Plourde B, Sarrazin J-F, Nault I, Poirier P. (2014). Sudden cardiac death and obesity. Expert Rev Cardiovasc Ther 12: 1099–1110.

  • Raal FJ. (2009). Pathogenesis and managenemt of the dyslipidaemia of the metabolic syndrome. Metab Syndr Relat Disord 7: 83–88.

  • Reule CA, Goyvaerts B, Schoen C. (2017). Effects of an L-arginine-based multi ingredient product on endothelial function in subjects with mild to moderate hypertension and hyperhomocysteinemia - a randomized, double-blind, placebo-controlled, cross-over trial. BMC Complement Altern Med 17: 92.

  • Silva MT, Ribeiro FP, Medeiros MA, Sampaio PA, Silva YM, Silva MT, Quintans JS, Quintans-Júnior LJ, Ribeiro LA. (2015). The vasorelaxant effect of p-cymene in rat aorta involves potassium channels. Sci World J 2015: 458080.

  • Simões FV, de Batista PR, Botelho T, Ribeiro-Júnior RF, Padilha AS, Vassallo DV. (2016). Treatment with high dose of atorvastatin reduces vascular injury in diabetic rats. Pharmacol Rep 68: 865–873.

  • Simor T, Lorand T, Gaszner B, Elgavish GA. (1997). The modulation of pacing-induced changes in intracellular sodium levels by extracellular Ca in isolated perfused rat hearts. J Mol Cell Cardiol 29: 1225–1235.

  • Sotnikova R, Bacova B, Vlkovicova J, Navarova J, Tribulova N. (2012). Sex differences in endothelial function of aged hypertriglyceridemic rats – effect of atorvastatin treatment. Interdiscip Toxicol 5: 155–158.

  • Soydinc S, Davutoglu V, Akcay M. (2006). Uncomplicated metabolic syndrome is associated with prolonged electrocardiographic QTc interval and QTc dispersion. Ann Noninvasive Electrocardiol 11: 313–317.

  • Štolc S, Šnirc V, Májeková M, Gáspárová Z, Gajdošíková A, Štvrtina S. (2006). Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress. Cell Mol Neurobiol 26: 1493–1502.

  • Tadic M, Ivanovic B, Cuspidi C. (2013) What do we currently know about metabolic syndrome and atrial fibrillation? Clin Cardiol 36: 654–662.

  • Tribulová N, Okruhlicová Ľ, Nováková S, Pancza D, Bernátová I, Pechanová O, Weismann P, Manoach M, Seki S, Mochizuki M. (2002). Hypertension-related intermyocyte junction remodeling is associated with higher incidence of low K+-induced lethal arrhythmias in isolated rat heart. Exp Physiol 87: 195–205.

  • Tribulová N, Fialová M, Dlugošová K, Knezl V, Okruhlicová L, Kristek F, Zicha J, Kuneš J. (2006). Myocardial gap junction remodelling in hypetriglyceridemic rat heart is associated with increased vulnerability to ventricular fibrillation. Cardiology 15: 32S–33S.

  • Tribulova N, Knezl V, Okruhlicova L, Slezak J. (2008). Myocardial gap junctions: targets for novel approaches in the prevention of life-threatening cardiac arrhythmias. Physiol Res 57: S1–S13.

  • Watanabe H., Tanabe N, Watanabe T, Roden D M, Sasaki S. (2008). Aizawa Y. Metabolic syndrome and risk of development of atrial fibrillation. Circulation 117: 1255–1260.

  • Wensley I, Salaveria K, Bulmer AC, Donner DG, du Toit EF. (2013). Myocardial structure, function, and ischaemic tolerance in a rodent model of obesity with insulin resistance. Exp Physiol 98: 1552–1564.

  • Witkowski FX, Leon LJ, Penkoske PA, Giles WR, Spano ML, Ditto WL, Wintre AT. (1998). Spatiotemporal evolution of ventricular fibrillation. Nature 392: 78–82.

  • Xu XR, Li KB, Wang P, Xu L, Liu Y, Yang ZS, Yang XC. (2016). The impact of different doses of atorvastatin on plasma endothelin and platelet function in acute ST-segment elevation myocardial infarction after emergency percutaneous coronary intervention. Zhonghua Nei Ke Za Zhi 55: 932–936.

  • Yilmaz H, Özcan KS, Sayar N, Kemaloglu T, Gungor B, Erer B, Yilmaz M, Gurkan U, Cakmak N, Oz D, Calik AN, Bolca O. (2015). Metabolic syndrome is associated with atrial electrical and mechanical dysfunction. Med Princ Pract 24: 147–152.

  • Zhang WL, Yan WJ, Sun B, Zou ZP. (2014). Synergistic effects of atorvastatin and rosiglitazone on endothelium protection in rats with dyslipidemia. Lipids Health Dis 13: 168.

  • Zúrová-Nedelčevová J, Navarová J, Drábiková K, Jančinová V, Petríková M, Bernátová I, Kristová V, Šnirc V, Nosáľová V, Sotníková R. (2006). Participation of reactive oxygen species in diabetes induced endothelial dysfunction. Neuroendocrinol Lett 27: 168–171.


Journal + Issues